title: Tetanus vaccines: WHO position paper – February 2017.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D003017:Clostridium tetani; D003362:Cost-Benefit Analysis; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D007116:Immunization, Passive; D007117:Immunization, Secondary; D015994:Incidence; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011247:Pregnancy; D013742:Tetanus / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D014944:World Health Organization; D014947:Wounds and Injuries / Q000150:complications / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D013745:Tetanus Toxoid